These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37844469)

  • 21. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
    Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis.
    Sohn W; Jun DW; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC
    Dig Dis Sci; 2015 Nov; 60(11):3340-50. PubMed ID: 26143342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of curcumin on the non-alcoholic steatohepatitis via inhibiting the M1 polarization of macrophages.
    Tong C; Wu H; Gu D; Li Y; Fan Y; Zeng J; Ding W
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S310-S317. PubMed ID: 34470535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
    Zhang Y; Wu B; Zhang H; Ge X; Ying S; Hu M; Li W; Huang Y; Wang L; Chen C; Shan X; Liang G
    J Cell Mol Med; 2018 Feb; 22(2):936-947. PubMed ID: 29077272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis.
    Yao Q; Li S; Li X; Wang F; Tu C
    Front Med (Lausanne); 2020; 7():71. PubMed ID: 32195263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway.
    Chyau CC; Wang HF; Zhang WJ; Chen CC; Huang SH; Chang CC; Peng RY
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31935815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
    Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
    Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets.
    Hwang S; He Y; Xiang X; Seo W; Kim SJ; Ma J; Ren T; Park SH; Zhou Z; Feng D; Kunos G; Gao B
    Hepatology; 2020 Aug; 72(2):412-429. PubMed ID: 31705800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice.
    Lee SM; Muratalla J; Karimi S; Diaz-Ruiz A; Frutos MD; Guzman G; Ramos-Molina B; Cordoba-Chacon J
    Cell Mol Life Sci; 2023 Jan; 80(2):39. PubMed ID: 36629912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of S-nitrosylation-induced PPARγ/SFRP5 pathway inhibition on the conversion of non-alcoholic fatty liver to non-alcoholic steatohepatitis.
    Wang H; Li F; Feng J; Wang J; Liu X
    Ann Transl Med; 2021 Apr; 9(8):684. PubMed ID: 33987382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH).
    Jindal A; Bruzzì S; Sutti S; Locatelli I; Bozzola C; Paternostro C; Parola M; Albano E
    Exp Mol Pathol; 2015 Aug; 99(1):155-62. PubMed ID: 26112094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice.
    Xu L; Chen Y; Nagashimada M; Ni Y; Zhuge F; Chen G; Li H; Pan T; Yamashita T; Mukaida N; Kaneko S; Ota T; Nagata N
    Metabolism; 2021 Dec; 125():154914. PubMed ID: 34656648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage immunophenotype but not anti-inflammatory profile is modulated by peroxisome proliferator-activated receptor gamma (PPARγ) in exercised obese mice.
    Silveira LS; Biondo LA; de Souza Teixeira AA; de Lima Junior EA; Castoldi A; Câmara NOS; Festuccia WT; Rosa-Neto JC; Lira FS
    Exerc Immunol Rev; 2020; 26():10-22. PubMed ID: 32139355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis.
    Lee S; Usman TO; Yamauchi J; Chhetri G; Wang X; Coudriet GM; Zhu C; Gao J; McConnell R; Krantz K; Rajasundaram D; Singh S; Piganelli J; Ostrowska A; Soto-Gutierrez A; Monga SP; Singhi AD; Muzumdar R; Tsung A; Dong HH
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35700043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization.
    Luo Y; Guo J; Jia W; Wu M; Yin F; Niu G; Shih DQ; Targan SR; Zhang X
    Oxid Med Cell Longev; 2021; 2021():3877617. PubMed ID: 35003513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.